All In Biotech

Drug Trial Radar · NCT02515318

Physiotherapy in Acute Exacerbation of Chronic Obstructive Pulmonary Disease

Effects of a Physiotherapy Program in Acute Exacerbation of Chronic Obstructive Pulmonary Disease

Last checked: Nov 20, 2026Latest source record: Jul 13, 2018 (this record)Source: ClinicalTrials.govMethods & limitations

Status unknown

Status

Status unknown

Enrollment

60

Planned (sponsor's estimate)

Start

Sep 2015

Primary completion

Mar 2017

Study completion Jul 2018

Sponsor

Lead sponsor
Universidad de GranadaAcademic, hospital or other
Sponsor type
Academic, hospital or other
First posted
Aug 4, 2015

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Not applicable
Allocation
Randomized
Model
Single group
Masking
Single (investigator)
Primary purpose
Treatment
Who can join
All sexes, from 40 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

Chronic Obstructive Pulmonary Disease (COPD) is projected to be the fifth leading burden of disease worldwide by the year 2020. An acute exacerbation of COPD (AECOPD) is defined as an acute event characterized by a worsening of the patient's respiratory symptoms that requires a modification in the medication. AECOPD are frequent (mean of 1-4 exacerbations each year). It increases in frequency with the severity of the disease. The objective of this study is to examine whether a physical therapy intervention can reduce impairment in patients with COPD during hospitalization due to an acute exacerbation.

Conditions

  • COPD

Interventions

  • Physiotherapy programOther

    The physiotherapy treatment will be performed during the hospitalization, every day during 45-60 minutes, and included: breathing exercises, electrostimulation in quadriceps with voluntary contraction and exercises with theraband.

  • Medical standard treatmentDrug

    The standard medical treatment consists on: Inhaled bronchodilators: Short acting inhaled β2 agonists ( salbutamol and terbutaline) and anticholinergic agents (ipratropium and oxitropium bromide). Glucocorticoids: Inhaled glucocorticoids including beclomethasone dipropionate, budesonide, flunisolide, fluticasone propionate and triamcinolone acetonide, depending on the expert criteria. \- Antibiotics: The antibiotics were administered according to the GOLD criteria including the β-lactamase inhibitor and fluoroquinolones.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Muscle strengthTime frame: Participants will be followed for the duration of hospital stay, an expected average of 9 days.
  2. Exercise capacityTime frame: Participants will be followed for the duration of hospital stay, an expected average of 9 days.

Locations

2 sites in 1 country. Site status is shown where the registry gives one.

  • University of Granada

    Granada, Spain · Recruiting

  • Department of Physical Therapy

    Granada, Spain · Recruiting

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.